• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

IL-17 Antibody Clears Psoriasis

N

natasa778

Senior Member
Messages
1,774
Brodalumab, a monoclonal antibody that targets the interleukin (IL)-17 receptor, was effective in moderate-to-severe plaque psoriasis in a phase III study, Amgen and AstraZeneca announced.

The trial's primary endpoint, a 75% improvement in the Psoriasis Area Severity Index (PASI 75) at week 12, was achieved by 83.3% of patients receiving a higher dose of brodalumab and by 60.3% of those given a lower dose, compared with 2.7% of patients on placebo.

In addition, the percentage of patients who had at least 90% improvement were 70.3%, 42.5%, and 0.9% in the three groups, respectively, while 41.9%, 23.3%, and 0.5% showed 100% improvement.

Brodalumab is a human monoclonal antibody that inhibits inflammatory signaling through the IL-17 pathway.

The trial, known as AMAGINE-1, included 661 patients who initially were randomized to receive subcutaneous brodalumab in dosages of 210 mg or 140 mg or placebo every 2 weeks...
Click to expand...

http://www.medpagetoday.com/Dermatology/Psoriasis/45737
 
You must log in or register to reply here.